Search research articles
Contact Us
Filters
Showing results (191-200 of 268) with videos related to
Page
of 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2021
Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
Vivek Subbiah, Justin F Gainor, Geoffrey R Oxnard, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis
Mark M Awad, Giulia C Leonardi, Sasha Kravets, et al.
JCO Precision Oncology
|
September 11, 2020
Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology
Jessica J Tao, Michael H Eubank, Alison M Schram, et al.
JCO Precision Oncology
|
September 15, 2018
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
Anna F Farago, Martin S Taylor, Robert C Doebele, et al.
The New England Journal of Medicine
|
October 23, 2023
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC
Caicun Zhou, Benjamin Solomon, Herbert H Loong, et al.
Cancer Discovery
|
August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
Nature Medicine
|
January 15, 2020
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon, Jeffrey W Clark, Jared Weiss, et al.
The Oncologist
|
April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective
Merel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Investigational New Drugs
|
March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2026
Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies
Jonas Willmann, Edward Christopher Dee, Lizza E L Hendriks, et al.
Page
of 27
Search research articles
Search
Showing results (191-200 of 268) with videos related to
Sort By:
Page
of 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2021
Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
Vivek Subbiah, Justin F Gainor, Geoffrey R Oxnard, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis
Mark M Awad, Giulia C Leonardi, Sasha Kravets, et al.
JCO Precision Oncology
|
September 11, 2020
Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology
Jessica J Tao, Michael H Eubank, Alison M Schram, et al.
JCO Precision Oncology
|
September 15, 2018
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
Anna F Farago, Martin S Taylor, Robert C Doebele, et al.
The New England Journal of Medicine
|
October 23, 2023
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC
Caicun Zhou, Benjamin Solomon, Herbert H Loong, et al.
Cancer Discovery
|
August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
Nature Medicine
|
January 15, 2020
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon, Jeffrey W Clark, Jared Weiss, et al.
The Oncologist
|
April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective
Merel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Investigational New Drugs
|
March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2026
Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies
Jonas Willmann, Edward Christopher Dee, Lizza E L Hendriks, et al.
Page
of 27